These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25970777)

  • 1. c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression.
    Cantrell MA; Ebelt ND; Pfefferle AD; Perou CM; Van Den Berg CL
    Oncotarget; 2015 May; 6(14):11863-81. PubMed ID: 25970777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model.
    Chen P; O'Neal JF; Ebelt ND; Cantrell MA; Mitra S; Nasrazadani A; Vandenbroek TL; Heasley LE; Van Den Berg CL
    PLoS One; 2010 May; 5(5):e10443. PubMed ID: 20454618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mouse model for luminal epithelial like ER positive subtype of human breast cancer.
    Kumar MJ; Ponvijay KS; Nandhini R; Nagarajan RS; Jose J; Srinivas G; Nagarajan P; Venkatesan R; Kumar K; Singh S
    BMC Cancer; 2007 Sep; 7():180. PubMed ID: 17880731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multipotent luminal mammary cancer stem cells model tumor heterogeneity.
    Bao L; Cardiff RD; Steinbach P; Messer KS; Ellies LG
    Breast Cancer Res; 2015 Oct; 17(1):137. PubMed ID: 26467658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JNK2 downregulation promotes tumorigenesis and chemoresistance by decreasing p53 stability in bladder cancer.
    Pan CW; Liu H; Zhao Y; Qian C; Wang L; Qi J
    Oncotarget; 2016 Jun; 7(23):35119-31. PubMed ID: 27147566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors.
    Ling H; Sylvestre JR; Jolicoeur P
    Oncogene; 2010 Aug; 29(32):4543-54. PubMed ID: 20562911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
    Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
    Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of JNK in a Trp53-dependent mouse model of breast cancer.
    Cellurale C; Weston CR; Reilly J; Garlick DS; Jerry DJ; Sluss HK; Davis RJ
    PLoS One; 2010 Aug; 5(8):e12469. PubMed ID: 20814571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.
    Faraldo MM; Romagnoli M; Wallon L; Dubus P; Deugnier MA; Fre S
    Breast Cancer Res; 2024 Jun; 26(1):91. PubMed ID: 38835038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms and protein expression of P53 and BRCA1 in preneoplastic and neoplastic rat mammary glands.
    Al-Dhaheri W; Hassouna I; Karam SM
    Oncol Rep; 2018 May; 39(5):2193-2200. PubMed ID: 29498408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.
    Xie X; Kaoud TS; Edupuganti R; Zhang T; Kogawa T; Zhao Y; Chauhan GB; Giannoukos DN; Qi Y; Tripathy D; Wang J; Gray NS; Dalby KN; Bartholomeusz C; Ueno NT
    Oncogene; 2017 May; 36(18):2599-2608. PubMed ID: 27941886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
    Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
    Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice.
    Yan H; Blackburn AC; McLary SC; Tao L; Roberts AL; Xavier EA; Dickinson ES; Seo JH; Arenas RB; Otis CN; Cao QJ; Lawlor RG; Osborne BA; Kittrell FS; Medina D; Jerry DJ
    Am J Pathol; 2010 Mar; 176(3):1421-32. PubMed ID: 20110418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8).
    Mitra S; Lee JS; Cantrell M; Van den Berg CL
    J Biol Chem; 2011 Apr; 286(17):15287-97. PubMed ID: 21357683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
    Wu J; Crowe DL
    Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transformation of enriched mammary cell populations with polyomavirus middle T antigen influences tumor subtype and metastatic potential.
    Drobysheva D; Smith BA; McDowell M; Guillen KP; Ekiz HA; Welm BE
    Breast Cancer Res; 2015 Oct; 17(1):132. PubMed ID: 26429062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
    Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
    Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.
    Verbeke S; Richard E; Monceau E; Schmidt X; Rousseau B; Velasco V; Bernard D; Bonnefoi H; MacGrogan G; Iggo RD
    Breast Cancer Res; 2014 Dec; 16(6):504. PubMed ID: 25527189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.